This review provides an overview of current diagnostic approaches (Section 2), specific therapies approved for ATTRv and ATTRwt amyloidosis (Section 3 and Section 4), and future therapeutic options (Section 5), with a focus on patients with ATTR-CM, including mixed phenotype patients with additional ATTR-PN. This evidence concerns the gene TTR and amyloidosis.